Pharmaceutically active compounds as Axl inhibitors

US8999982B2 · kind B2 · utility

Assignees

• Lead Discovery Center GmbH · DE
• Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US

Inventors

• Carsten Schultz-Fademrecht · Pomezia, IT
• Bert Klebl · Dortmund, DE
• Axel Choidas · Herdecke, DE
• Uwe Koch · Roma, IT
• Jan Eickhoff · Herdecke, DE
• Alexander Wolf · Oberkochen, DE
• Axel Ullrich · Portola Valley, US

Key dates

• Filing date: Aug 26, 2011
• Grant date: Apr 7, 2015
• Expiry date: Aug 26, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.